{"id":123860,"date":"2020-10-14T16:00:04","date_gmt":"2020-10-14T13:00:04","guid":{"rendered":"https:\/\/ldaily.ua\/ru\/?post_type=news&#038;p=123860"},"modified":"2020-10-13T16:41:50","modified_gmt":"2020-10-13T13:41:50","slug":"gsk-i-vir-biotechnology-perehodyat-do-fazy-3-doslidzhen-antytil-proty-covid-19","status":"publish","type":"news","link":"https:\/\/ldaily.ua\/en\/news\/novosti\/gsk-i-vir-biotechnology-perehodyat-do-fazy-3-doslidzhen-antytil-proty-covid-19\/","title":{"rendered":"&#8220;GSK&#8221; and &#8220;Vir Biotechnology&#8221; go to phase of the 3 studies of antibodies against COVID-19"},"content":{"rendered":"<p>Companies Vir Biotechnology, Inc. and GlaxoSmithKline plc (GSK) announced the global extension to phase 3 of the COMET-ICE study, which evaluates the effectiveness of monoclonal antibodies &#8211; VIR-7831 for early treatment of COVID-19 in patients at high risk of hospitalization. VIR-7831 (also known as GSK4182136) is the fully human monoclonal antibody against SARS-CoV-2, selected for its ability to neutralize the virus, to kill infected cells and reach the high concentrations in the lungs (one of the main foci of infection). Following the positive evaluation of the safety data at the initial stage of the Independent Data Monitoring Committee on 30 September 2020, COMET-ICE&#8217;s registration study will now be expanded worldwide to include additional clinical bases in the North and South America as well as Europe. Prior to this expansion, COMET-ICE, originally planned as the Phase 2-3 study, took place only in the United States. It is expected that in early 2021 the product will be available for limited clinical use.<\/p>\n<p>The increased risk of the hospitalization is judged by such comorbidities as diabetes, obesity, renal or heart failure, chronic obstructive pulmonary disease, bronchial asthma, age over 55 years. In addition to VIR-7831, the immunology company is also developing antibodies against hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.<\/p>\n","protected":false},"featured_media":123861,"menu_order":0,"template":"","newscat":[9],"newstag":[24349,27393,27121,29431],"issues":[],"class_list":["post-123860","news","type-news","status-publish","has-post-thumbnail","hentry","newscat-novosti","newstag-covid-19","newstag-gsk","newstag-sars-cov-2","newstag-vir-biotechnology"],"_links":{"self":[{"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/news\/123860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/media\/123861"}],"wp:attachment":[{"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/media?parent=123860"}],"wp:term":[{"taxonomy":"newscat","embeddable":true,"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/newscat?post=123860"},{"taxonomy":"newstag","embeddable":true,"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/newstag?post=123860"},{"taxonomy":"issues","embeddable":true,"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/issues?post=123860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}